Talk Title: Metaproteomic tools to study individual human gut microbiota.
Prof. Daniel Figeys is a Canada Research Chair in Proteomics and Systems Biology. He is Professor and Chair in the Department of Biochemistry, Microbiology and Immunology in the Faculty of Medicine at the University of Ottawa. He is also cross-appointed in the Department of Chemistry and Biomolecular Sciences at the University of Ottawa. He is Senior Fellow in the Canadian Institute for Advanced Research. Daniel is interested in the development of proteomics and systems biology technologies and their applications in microbiome, Inflammatory Bowel Disease, circadian cycle and cardiovascular diseases. He has published over 170 articles, cited over 12,000 times, and has an H-index of 49.
Host–microbiota interactions have been linked to a growing list of diseases, including inflammatory bowel diseases (IBD), obesity, etc.. We are interested in studying the molecular changes that occurs in host and microbiota during gut dysbiosis, the effect of diet and to develop screening techniques for microbiota. To date our understanding of the microbiota has been driven by Next-generation sequencing (NGS). In contrast, the application of metaproteomics primarily due to the the lack of easy-to-use metaproteomic computational platforms that can handle the very large microbial genomic databases. We will first report on the development of a metaproteomics protein identification platform called Metalab and its application for deep metaproteomic analysis. Then we will report on RapidAIM, an ex vivo assays to study the effects of drugs on the human gut microbiota. Series of compounds can be screened against individual microbiota allowing the characterisation of the microbiota changes induced by the compounds.